Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ceccon

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
AIDS Health Promotion Exchange|January 1, 1994
Country watch. BrazilC Ceccon
Science (New York, N.Y.)|December 14, 1979
New experimental data on atmospheric propagationR R Shannon, C Ceccon, W S Smith, et al.
Texas Heart Institute Journal|January 1, 1993
Congenital circumflex coronary artery fistula with drainage into the left ventricleL A Teno, J L Santos, R B Bestetti, et al.
ESMO Open|April 11, 2025
Claudin 18.2: a promising actionable target in biliary tract cancersV Angerilli, D Sacchi, M Rizzato, et al.
ESMO Open|June 20, 2025
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trialR Fazio, G Randon, F Bergamo, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
AIDS Health Promotion Exchange|January 1, 1994
Country watch. BrazilC Ceccon
Science (New York, N.Y.)|December 14, 1979
New experimental data on atmospheric propagationR R Shannon, C Ceccon, W S Smith, et al.
Texas Heart Institute Journal|January 1, 1993
Congenital circumflex coronary artery fistula with drainage into the left ventricleL A Teno, J L Santos, R B Bestetti, et al.
ESMO Open|April 11, 2025
Claudin 18.2: a promising actionable target in biliary tract cancersV Angerilli, D Sacchi, M Rizzato, et al.
ESMO Open|June 20, 2025
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trialR Fazio, G Randon, F Bergamo, et al.
Pageof 1